EU/3/18/1974

Table of contents

About

On 22 February 2018, orphan designation (EU/3/18/1974) was granted by the European Commission to Takeda Pharma A/S, Denmark, for 6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one monocitrate (also known as TAK-659) for the treatment of acute myeloid leukaemia.

The sponsor’s address was updated in August 2020.

Key facts

Active substance
6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one monocitrate
Disease / condition
Treatment of acute myeloid leukaemia
Date of first decision
22/02/2018
Outcome
Positive
EU designation number
EU/3/18/1974

Sponsor's contact details

Takeda Pharma A/S
Delta Park 45
2665 Vallensbaek Strand
Hovedstaden
Danmark
Tel: +45 4677 1111
E-mail: kristina.stovring@takeda.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating